Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPECT-CMV
NCT07488481Phase 1Not yet recruiting
- Sponsor
- University Health Network
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYN002 in cytomegalovirus infection (CMV), sponsored by University Health Network. Primary endpoint: Graft function at 4 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SYN002
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07488481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488481.